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S_.mary A review was carried out of the published literature on survival rates for cancer in relation to
patterns of organisation of medical care, specifically treatment at specialist centres or at hospitals treating
larger numbers of patients and treatment by protocol, usually within the context of a clinical trial. Centralised
referral or entry to trials was frequently associated with a higher survival rate, particularly for the less
common cancers, and was never found to be associated with a lower survival rate. Few studies were identified
for any one cancer site and some antedated current methods of treatment. At a time when the health service in
the United Kingdom is undergoing far-reaching organisational change, further research is needed to establish
the most beneficial patterns of care for people with cancer. Population-based cancer registries are an
invaluable source of data for such studies.
In the United Kingdom, as in several other countries, the
organisation of the health service is undergoing far-reaching
change. A new system, such as the British one of contracts
for services with demarcation between purchasers and pro-
viders of health care, can result in changes to established
patterns of referral. It is essential to obtain adequate inform-
ation to ensure that the patterns of medical care which are
adopted are those which result in the best outcome for
patients. In oncology it is particularly important to determine
the effects on survival (i) of treatment at specialised centres
or in smaller district hospitals and (ii) of standardisation of
treatment, most commonly through participation in multi-
centre controlled trials.
The literature on these topics is growing at an increasing
rate and is distributed through a wide range of sometimes
relatively inaccessible publications. The most recent extended
review of these topics (Stiller, 1992) did not cover studies
published since 1990. Moreover, it has since been found that
a few earlier studies had been overlooked, including a -series
of papers from the cancer registry of the former German
Democratic Republic (GDR) that appeared in German jour-
nals and were seldom quoted elsewhere. The purpose of the
present article is to assemble as complete a collection as
possible of relevant studies and to review the body of
evidence thus obtained.
Materal and metbod
The starting point was the collection of reports from
population-based studies assembled for the 1992 review,
which was derived largely from manual searches of major
English-language general medical and oncological journals
and from the bibliographies in relevant articles from these
journals. This process has continued, but has been supple-
mented in several ways.
Population-based cancer registries whose data were already
Inown to have been used for such studies were asked for
details of futher publications which may have been missed,
together with any unpublished studies; this yielded several
published papers for review but no unpublished studies were
found.
Studies of patients ascertained from reasonably complete
population-based cancer registries have the best chance of
indicating what is happening to the total population of
patients in a given geographical area, but in some countries a
relatively small proportion of the population has been
covered by such registries. For this reason, the scope of the
review was widened to include studies using data which were
not population based, notably the large surveys of patterns
of care carried out in the United States (Kramer, 1981) and
Italy (Liberati et al., 1983) for which the study populations
consisted of patients treated at representative samples of
hospitals. More recently, population-based patterns of care
studies have begun in the United States using data from the
SEER Program cancer registries (Harlan, 1992), while cancer
registries in several European countnres are contributing to
the international 'Eurocare' study (Chouillet et al., 1994).
Analyses of survival in relation to organisational factors have
yet to appear from either of these studies.
Finally, for 1984 onwards two electronic databases, Med-
line and Embase, were searched on the Silver Platter Cancer
CD. Tables I-XI contain 32 references included on Cancer
CD and already known to the author before searching began.
Of these, 14 (44%) could be retrieved by a search of medical
subject headings (MESH) containing at least one of the terms
survival, outcome, prognosis, mortality and at least one of
hospitals, protocols, cancer care facilities, referral, health
services. Four additional references not previously known
were found in this search, making a total of 18 publications,
and these accounted for 2.8% of the total of 649 references
so indexed. Extending the search to other fields or by addi-
tional keywords increased the total number of references
retrieved by a much greater proportion than it did the
number ofrelevant publications found. This is a considerably
worse result than that found by Silagy (1993) in searching for
randomised controlled trials in primary care and probably
reflects inconsistency in allocation of keywords.
Results
Most published studies are concerned with cancers at only
one or two sites. The results for adults are presented first.
Table I-IX give references, numbers of patients and
variables studied for sites with more than one published
study, with sites in the same order as they appear in the
International Classification of Diseases. Table X gives similar
information for sites with only one study each. There then
follows a review of the evidence relating to childhood
cancers, for which details of individual studies are given in
Table XI. Results quoted are taken from the original publica-
tions unless otherwise stated.
Stomach (Table I)
Slisow et al. (1987) analysed data on 6,220 patients from the
GDR, of whom 21.0% underwent radical surgery. This
group was classified by the number of radical operations per
year in surgical units. Operative mortality was 15.2% in units
with 20 or more operations, 21.6% in three with 5-19 opera-
tions and 22.4% in those with four or fewer operations. This
trend was not quite significant at the 0.05 level (reanalysis by
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Table I Studies of stomach cancer
Years of No. of
Reference diagnosis Setting patients Variables studied Outcome measures
Slisow et al. (1987) 1976 Former GDR 6,220 No. of resections Operative mortality;
at surgical unit 5 year survival
Ward et al. (1992) 1976-80 West Midlands. 1,209 Entry to trial Actuarial survival
England
present author: x7 = 3.66 on 1 d.f.). Five year survival rates
were compared for all patients referred to the three groups of
surgical units, but these figures are uninterpretable as there
was wide variation between groups in the proportion of
patients who had surgery. It is clear, however, that 5 year
survival among the patients who had radical surgery and
survived the post-operative period did not vary with size of
unit. The units performing most operations had a higher
proportion of patients with stage I disease and a lower
proportion of patients with stage IV disease among the total
of all patients referred to them; it was not stated whether this
relationship also obtained for patients who had radical
surgery, and stage was not allowed for in the analyses.
During 1976-80, 249 patients from 13 of the 22 districts in
the West Midlands region of England were entered in the
first British Stomach Cancer Group trial and their actuarial
survival was compared with that of 960 concurrent non-trial
patients from the same districts (Ward et al., 1992). The trial
patients had a higher survival rate and the difference almost
attained statistical significance. However, when strict criteria
of eligibility for the trial were applied, the 217 eligible
patients included in the trial had a very similar survival rate
to the 493 who were not included. The greatest reduction in
number among the non-trial group was due to the criterion
of fitness, which rendered 212 patients ineligible, over half of
them because of death within 28 days of operation.
Colorectal (Table II)
Hkama et al. (1989) found wide variations in survival rates
for colon cancer between the 21 hospital districts of Finland
in which the patients resided. Districts were classified as
university and non-university, with and without a radio-
therapy unit. Much of the variation in survival was at-
tributable to differences in age and stage distribution, but
when these and other variables were taken into account in
multivariate analysis there was still a significant, though
small, effect of type of district. The fitted 5 year relative
survival rates allowing for age and stage ranged from 43% in
university districts to 38% in non-university districts without
a radiotherapy unit.
Mohner and Slisow (1990) classified districts of residence
of patients with rectal carcinoma in the GDR according to
an index ofcentralisation of treatment, which was a weighted
average of the number of patients with the disease (resident
anywhere) at each of the hospitals treating patients resident
in the district in question. Districts with a centralisation
index of at least 60, i.e. whose patients were on average
treated at centres seeing at least 12 cases per year of rectal
carcinoma over the 5 year study period, had a higher 5 year
relative survival rate but the statistical significnce of this
was not quoted.
Launoy et al. (1992) found a significantly lower survival
rate for women with colorectal cancer, though not for men, if
they lived in a rural rather than urban area in the French
department of Calvados. Residents of rural areas were less
likely to be treated at a specialist centre, but women from
these areas also had more advanced disease at diagnosis.
Place of treatment had no effect on survival and the poor
prognosis for women from rural areas was attributed to
delay in diagnosis.
Pickering et al. (1992) found significant variation in sur-
vival among residents of the ten districts of the Wessex
region in England. No attempt was made to relate these
differences to the presence of a university hospital in one
district or to the level of provision of oncology services in
general. It was noted, however, that the district with the
highest survival rate for colon cancer had been the setting for
a study of the effectiveness of screening for colorectal cancer
during the study period.
Kingston et al. (1992) compared patients treated by sur-
geons in teaching and district general hospitals in north-west
England. Operative mortality was similar in the two groups,
as was 5 year survival whether the end point was death from
any cause or from colorectal cancer. Teaching hospital
patients had poorer performance status, but non-teaching
hospitals had higher proportions of emergency patients and
of patients aged over 80; no formal allowance was made for
these factors in the analysis.
Lung (Table III)
In a proportional hazards analysis of 1,403 patients with
non-small-cell lung carcinoma in New Hampshire and Ver-
mont, those who lived 25-49 miles from the nearest cancer
centre had a non-significantly higher mortality rate ratio than
the reference group living within 25 miles (1.14; 95%
confidence interval 0.97-1.35, P = 0.122) and patients living
Table H Studies of colorectal cancer
Years of No. of
Reference diagnosis Setting patients Site Variables studied Outcome measures
Hakama et al. (1989) 1970-81 Finland 7,078 Colon Type of hospital Actuarial
in district of relative survival
residence
Mohner & Slisow (1990) 1976-80 Former GDR 15.731 Rectum Degree of Five year survival
centralised
treatment in district
Launoy et al. (1992) 1978-84 Calvados. France 1.331 Colorectal Type of hospital; Actuanral survival
urban/rural
residence
Pickering et al. (1992) 1979-84 Wessex region, 6.239 Colon District of Actuarial survival
England 3.203 Rectum residence
Kingston et al. (1992) 1981 -83 North-west 567 Colorectal Type of hospital Operative mortality;
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Table I Studies of lung cancer
Years of No. of
Reference diagnosis Setting patients Variables studied Outcome measures
Greenberg et al. (1991) 1973-76 New Hampshire 1,658 Distance from cancer Actuarial survival
and Vermont, centre; type of
USA hospital
Davis et al. (1985) 1977-79 Washington 549 Entry to trial Actuarial survival
State, USA
Romano & Mark (1992) 1983-86 California, USA 12,439 Type of hospital; Post-operative
number of patients mortality
at hospital
at least 50 miles from a cancer centre had a similarly raised
ratio (1.16; 95% confidence interval 0.97-1.39, P=0.101)
(Greenberg et al., 1991). Combining these two results gives a
significantly raised mortality rate ratio of about 1.15 for
patients living at least 25 miles from a cancer centre. Patients
living further from a university cancer centre were less likely
to be treated there. Patients diagnosed in university centres
underwent more staging procedures and tended to be classi-
fied in a higher stage than those diagnosed elsewhere, and
when stage was allowed for there were significantly lower
mortality rate ratios at these centres compared with other
hospitals for both non-small-cell (0.81, 95% confidence inter-
val 0.71-0.91) and small-cell tumours (0.71, 0.55-0.91)
(Greenberg et al., 1991). Stage-specific groups at university
hospitals might, however, have contained more patients with
an inherently relatively good prognosis; when performance
status rather than stage was allowed for as a measure of
disease severity, university hospital patients did not have any
apparent survival advantage. The analyses allowing for stage
and performance status were not carried out for place of
residence and so it was impossible to tell whether the better
prognosis of patients living relatively close to a university
hospital might have been related to earlier diagnosis.
In Washington State, Davis et al. (1985) found a signifi-
cantly higher survival rate for patients with non-small-cell
lung cancer if they were included in a clinical trial, with 2
year survival rates of 82% for trial and 50% for non-trial
patients. In multivariate analysis, the advantage for trial
patients reained after adjustment for age, sex, tumour size,
nodal involvement and whether or not radiotherapy was
given as a first course of treatment.
In California, Romano and Mark (1992) found a trend
towards lower post-operative mortality in hospitals treating
larger numbers of cases of lung cancer both among patients
undergoing pneumonectomy and among those having lesser
resections, though it was acknowledged that disease severity
might have been an unmeasured confounder.
Breast (Table IV)
Karjalainen (1990) analysed the survival of women with
breast cancer diagnosed in Finland during 1970-81 accord-
ing to the same classification of district of residence as that
used in the study of colon cancer by Hakama et al. (1989).
Women who lived in a district where there was a university
hospital with modern radiotherapy facilities had a higher
survival rate, and this difference remained significant when
allowance was made for age and for localised versus non-
localised tumours.
Ebeling et al. (1982) studied survival by hospital of treat-
ment for women in Berlin with breast cancer diagnosed
during 1975 and 1976. Overall, 5 year relative survival allow-
ing for age was significantly higher at comprehensive cancer
centres (76%) than at other hospitals (64%). For patients
treated in hospitals with fewer than 20 new cases per year the
survival rate was 59%. The survival advantage of treatment
at a specialist centre was significant for stages I, II and
III-IV combined. The advantage for patients treated at cen-
tres with at least 20 new cases per year was significant only
for stage III-IV.
In Piedmont, Italy, during 1979-81, there was no differ-
ence in survival between women treated at private hospitals
or at public hospitals with varying numbers of cases during
the study period in a multivariate analysis which also
included age, year of diagnosis, marital status, occupation,
size of town of residence and area of birth (Boffetta et al.,
1993)
Bonett et al. (1991), in a study of infiltrating ductal car-
cinoma in South Australia, found that the survival rate was
significantly lower at large public hospitals, which would
have included teaching hospitals, than at large private hos-
pitals; survival rates at maler hospitals were midway
between those for the other two groups. When multivariate
analysis was crried out allowing for age, tumour size and
number of nodes involved, the effect of hospital type was no
longer significant. The large private hospitals had a higher
proportion of patients from districts of high socioeconomic
status, but this was not allowed for in the analysis of survival
despite the fact that several other studies have found higher
social class to be a favourable prognostic factor (Marshall &
Funch, 1983; Kaxjalainen & Pukkala, 1990).
Basnett et al. (1992) compared management and outcome
for women presenting at a teaching and a non-teaching
centre within the North-East Thames region of England.
Table IV Studies of breast cancer
Years of No. of
Reference diagnosis Setting patients Variables studied Outcome measures
Karjalainen (1990) 1970-81 Finland 16,678 Type of hospital Actuarial relative
in district of survival
residence
Ebeling et al. (1982) 1975-76 Berlin, 944 Type of hospital; Actuarial relative
former GDR number of patients survival
at hospital
Boffetta et al. (1993) 1979-81 Piedmont, Italy 4,764 Type of hospital Actuarial survival
Bonett et al. (1991) 1980-86 South Australia 2,589 Type of hospital Actuarial relative
survival
Basnett et al. (1992) 1982-86 NE Thames region, 999 Type of hospital Actuarial survival
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Table V Studies of cervical cancer
Years of No. of
Reference diagnosis Setting patients Variables studied Outcome measures
Chu et al. (1982) 1974-78 Washington State, 369 Type of hospital Three year
USA actuarial survival
Hanks et al. (1983. 1973. 1978 Selected hospitals. 1.558 Number of patients Four year actuarial
1985); USA at hospital; facilities survival; 4 year
Diamond et- al. (1991); at hospital pelvic recurrence
Lanciano et al. (1991) rate
They found significantly higher risks of relapse and death at
the non-teaching centre which remained after adjustment for
age, stage and operation.
Cervix (Table V)
In a study of women with stage I cervical cancer in Washing-
ton State (Chu et al., 1982), survival was not related to
whether they were treated at a hospital with a larger number
of new cancer patients (all sites) per year, at one classified in
a high peer group by the Washington State Hospital Com-
mission or at one with a cancer programme approved by the
American College of Surgeons.
The Patterns of Care Outcome Study, also in the United
States, compared a sample of 706 patients from 163 treat-
ment centres (the 'regular survey') with 298 patients from five
institutions each treating more than 50 new cases of cervical
cancer (the 'extended survey') in 1973. There were only small
differences between the two groups in 4 year survival and 4
year pelvic recurrence-free survival for stages I and II, but
for stage III the survival rate was 52% among 71 patients in
the extended survey, significantly higher than the 33% sur-
vival among 103 patients in the regular survey; there was also
significantly higher recurrence-free survival in the extended
survey (Hanks et al., 1983; Lanciano et al., 1991). When a
further sample of 565 patients treated at 120 centres (of all
sizes) in 1978 was compared with the 1973 extended survey,
pelvic recurrence-free survival was si ntly lower than
among stage II and stage III patients treated at the large
centres 5 years earlier (Lanciano et al., 1991). No differences
in survival between the three study populations were quoted
for stage I, and the surveys did not include stage IV. Within
the 1978 survey, numbers of patients per physician, tech-
nologist or physicist at a treatment centre were unrelated to
survival (Diamond et al., 1991).
Ovary (Table VI)
Among women treated at 31 Italian hospitals (Liberati et al.,
1985), survival rates were very similar for those at centres
with or without specialist oncological facilities, both for stage
I-II and for stage Il-IV tumours.
In a much larger, population-based series of women in the
west of Scotland (Gillis et al., 1991), those with stage I-II
tumours diagnosed in 1974 had significantly higher 10 year
survival (adjusted for age, stage and histology) if they were
treated at a teaching hospital, but there was no difference for
stage III-IV. Data on stage were not available for 1975-87,
but the overall improvement in 3 year survival of women
under 64 between 1975 and 1987 was greater at teaching
hospitals than elsewhere, and for patients aged 55-64 this
was statistically significant. A subsequent population-based
study included women throughout Scotland with ovarian
cancer diagnosed in 1987 (Junor et al., 1994). In a propor-
tional hazards analysis adjusted for age and stage, patients
seen initially by a gynaecologist had a significantly higher
survival rate, as did those whose surgery was performed by a
gynaecologist and those who were referred to a combined
clinic rather than to an individual specialist post-operatively.
Platinum chemotherapy was more likely to be given to
patients at combined clinics, but the survival advantage for
patients seen at these clinics remained after adjustment for
type of chemotherapy.
The Danish Ovarian Cancer group covers about two-thirds
of the population of Denmark. The group registered 120
women with stage I-II tumours and 361 with stage III-IV
who were eligible for entry in trials during 1981-84. For
stage I-LI there was no difference in actuarial survival
between randomised and non-randomised patients, but
among stage III-IV patients those who were randomised had
a significantly higher survival rate (Bertelsen, 1991). When
the comparison for stage III-IV was restricted to patients
who received combination chemotherapy, which was given to
all who were randomised but to only 47% of those who were
not, the difference disappeared; many of the non-randomised
patients were too ill to start treatment, but results were not
reported for randomised patients compared with those who
received treatment of any type but were not randomised.
In south-east Sweden during 1984-87, women with stage
III-IV tumours had a higher survival rate if they received
Table VI Studies of ovarian cancer
Years of No. of
Reference diagnosis Setting patients Variables studied Outcome measures
Liberati et al. (1985) 1978-79 Italy, 159 Type of hospital Actuarial survival
31 hospitals
Gillis et al. (1991) 1974-87 West of Scotland 3,155 Type of hospital Actuarial survival
Junor et al. (1994) 1987 Scotland 479 Speciality of doctor; Actuarial survival
type of clinic
Bertelsen (1991) 1981-84 Denmark, 481 Entry to trial Actuarial survival
catchment area
of Danish
Ovarian Cancer
Group
Hogberg et al. (1993) 1984-87 South-east 332 Protocol treatment Actuarial survival
Sweden
Nguyen et al. (1993) 1983 Selected hospitals, 5,156 Specialty of doctor Actuarial survival
USA
Eisenkop et al. (1992) 1985-88 USA, 14 hospitals 250 Specialty of doctor Actuarial survival356 C.A. STILLER
treatment according to the current protocol, but there was no
effect of protocol on survival for stages I-II (Hogberg et al.,
1993). It was possible that the patients who received protocol
treatment were in better general health at diagnosis, but this
factor could not be incorporated in the analysis.
In a study of over 5,000 women with ovarian carcinoma
who were treated at hospitals in the United States with
established cancer programmes, survival of those with stage I
tumours did not vary with specialty of the treating physician,
but for women with higher stage tumours survival was
significantly better if they were treated by a gynaecological
oncologist or an obstetrician/gynaecologist rather than by a
general surgeon (Nguyen et al., 1993). In a proportional
hazards analysis of a smaller series of women with stage HIC
or IVA diease treated in hospitals in California and Col-
orado, survival rates were sigificntly higher for patients of
gynaecological oncologists (Eisenkop et al., 1992), and this
was accounted for by the greater probability of optimal
cytoreduction.
Prostate (Table VII)
In Finland during 1970-81 the survival rate for prostate
cancer varied widely between residents of the 21 hospital
districts (Karjalainen, 1990). The variation did not appear to
be related to whether there was a university hospital or
radiotherapy centre in the district, and after adjustment for
age and extent of disease the distribution of survival rates
between districts could be explained by random variation.
In the Patterns of Care Study of men treated with radio-
therapy in the United States during 1973-76 (Leibel et al.,
1984), patients treated at centres which had a linear
accelerator had a recurrence rate of 33% compared with
42% at centres where the best equipment was a cobalt
machine, a difference which just achieved statistical signi-
ficance (P = 0.049). There was no significant difference in
recurrence rates between university, community and other
hospitals nor between centres with more or fewer than 350
patients (all sites) per year. Stage was apparently not allowed
for in these analyses. In a later survey of men treated in
1978, overall survival, though not recurrencefree survival,
was significantly better at radiotherapy centres with a larger
number of patients per physicist when stage was allowed for
(Diamond et al., 1991).
Testis (Table VIII)
Among the 246 men with any type of germ-cell testicular
cancer in the Irish Testicular Tumour Registry, patients
managed by a urologist had a significntly higher 4 year
survival rate (76%) than those who were not (69%) (Thorn-
hill et al., 1988a); among the subgroup of patients treated by
a urologist at the hospital to which they originally presented,
4 year survival was 81%. Survival rates were the same (71%)
regardless of whether or not an oncologist was involved.
Patients who received unorthodox chemotherapy or a
reduced dose of a standard regimen had a markedly lower
survival rate, but reasons for non-standard treatment were
not specfied, though stage was allowed for.
In a multivariate analysis of 200 men with metastatic
non-seminomatous tumours who were entered in the
Swedish-Norwegian Testicular Cancer Project, the 91 who
were treated at a single large institution had a significantly
lower risk of dying from or with testicular cancer (Aass et
al., 1991); the difference was largely confined to patients who
had large primary tumours.
In the west of Scotland during 1975-89, men with non-
seminomatous germ-cell tumours treated at the major unit
with 53% of all patients had a significantly higher survival
rate (Harding et al., 1993); 5 year survival at this unit was
87%, compared with 73% elsewhere. Tumour stage was
allowed for in this analysis. The proportion of patients
receiving nationally agreed protocol treatment was much
higher at the largest unit (97%) than elsewhere (61%); how-
ever, when the analysis was confined to those who received
protocol treatment, the major unit still had a significantly
lower relative mortality rate compared with other hospitals
(0.35, 95% confidence interval 0.19-0.65).
Hodgkin's disease (Table IX)
Davis et al. (1987) compared 2,278 patients registered by
comprehensive cancer centres in the United States with 3,607
patients from other hospitals in cancer registries of the SEER
Program. The cancer centres series had a significantly higher
survival rate in a multivariate analysis which included age,
sex, ethnic group, stage and histological subtype. At 5 years,
survival was 77% for the cancer centre patients and 63% for
those in the SEER senes. In the Patterns of Care Study, also
Table VII Studies of prostate cancer
Years of No. of
Reference diagnosis Setting patients Variables studied Outcome measures
Karjalainen (1990) 1970-81 Finland 9,105 Type of hospital in Actuarial relative
district of residence survival
Leibel et al. (1984) 1973-76 Selected hospital 682 No. of patients and Actuarial
USA type of radiotherapy recurrence-free
equipment at survival
hospital; type of
hospital
Diamond et al. (1991) 1978 Seected hospitals, 770 No. of patients Five year survival;
USA per hospital 5 year
recurrence-free
survival
Table VIII Studies of testicular cancer
Years of No. of
Reference diagnosis Setting patients Variables studied Outcome measures
Thornhill et al. (1988a) 1980-85 Irish Republic 246 Standard protocols; Actuarial survival
specialty of doctor
Aass et al. (1991) 1981-86 Sweden and 200 Size of treatment Actuarial survival
Norway, 14 centre
hospitals
Harding et al. (1993) 1975-89 West of Scotland 440 Size of Actuarial survival
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Table IX Studies of Hodgkin's disease
Years of No. of
Reference diagnosis Setting patients Variables studied Outcome measures
Davis et al. (1987) 1977-82 21 cancer centres 5,885 Type of hospital Actuarial survival
and SEER
registry areas,
USA
Hanks et al. (1985) ? Selected hospitals, 333 Radiotherapy Recurrence-free
USA equipment in survival
hospital
in the United States (Hanks et al., 1985), the stage-adjusted
recurrence rate was 29% among patients treated at centres
with a linear accelerator or betatron compared with 37% for
those with only a cobalt-60 machine, a non-significant
difference (P = 0.11).
Miscellaneous sites (Table X)
Edge et al. (1993) found only a very weak, non-significant
trend of decreasing mortality with number of cases per hos-
pital among patients who had a resection for pancreatic
cancer in 26 American university hospitals.
In the Patterns of Care Outcome Studies of laryngeal
cancer in the United States, hospitals were scored for how
closely they adhered to best current practice in pretreatment
investigations and in treatment. In the 1972-74 survey,
patients with stage III and IV tumours who were treated at
higher scoring centres had a significantly higher 3 year
recurrence-free survival rate, but by 1978 this difference had
disappeared, while in both surveys there was no difference
between groups of centres for stage I and II patients (Lustig
et al., 1984, 1991). In 1973-74, recurrence-free survival was
70-72% at radiotherapy centres whose best equipment was
an accelerator or relatively high-energy cobalt machine, com-
pared with 52% at those with only a lower energy cobalt
machine (Lustig et al., 1984); however, this analysis was
apparently not adjusted for tumour stage, and it was not
repeated in the 1978 survey. In 1978, though not in 1973,
patients with stage II glottic carcinoma had a higher
recurrence-free survival rate if treated at a hospital with over
550 cancer patients (all sites) per year (Lustig et al., 1991); as
this effect did not obtain for supra- and subglottic stage II
tumours, or for stage I tumours in either site, it may well
have been a chance finding.
Gill et al. (1988) studied survival rates for 407 patients
with osteosarcoma diagnosed in the South Thames regions of
England during 1963-82. For the 194 patients aged under 65
who were diagnosed during 1968-82, a proportional hazards
analysis included as a variable whether a patient was treated
at a major centre, defined as a teaching hospital or one which
treated at least a specified minimum number of patients in
the study with chemotherapy. There was no significant effect
of type of centre on survival, but the study period preceded
the substantial improvements in prognosis attributable to
more modern chemotherapy. Among the 121 patients aged
under 25 the hazard ratio associated with major centres was
0.61; this result was not statistically significant but the
number of cases analysed was small.
Brewer et al. (1971) studied 244 women in Illinois who had
choriocarcinoma or invasive hydatidiform mole diagnosed
during 1962 onwards. Of these, 151 were treated initially at a
single specialist centre and the other 93 were distributed
between 82 different hospitals. A very high success rate was
achieved everywhere for non-metastatic choriocarcinoma, but
for metastatic choriocarcinoma the crude failure rate was
17% (9/53) at the specialist centre compared with 57% (31/
54) elsewhere. For non-metastatic invasive mole, the failure
rates were 0% (0/61) at the centre and 31% (5/16) elsewhere,
while for metastatic invasive mole they were 0% (0/18) at the
specialist centre and 45% (5/11) elsewhere. These were pre-
sented as highly significant differences but they should be
interpreted cautiously as the interval from diagnosis to
failure was unspecified and follow-up would have been very
short for some patients.
In a study of 574 men with bladder cancer diagnosed in
1982 in the South Tlames regions of England, survival did
not differ between patients of urologists and those of other
surgeons (Gulliford et al., 1991).
In Finland during 1979-85, 71% of the 569 patients with
multiple myeloma aged up to 70 lived in districts where it
was local policy to enter patients with this disease in a
clinical trial; 79% of the patients from these districts were
actually included in the tnals (Karjalainen & Palva, 1989).
The 5 year relative survival rate of 38% for residents of the
trial disticts, irrespective of whether they were actually
included in the trials, was significantly higher than the 28%
survival for those from non-trial districts. The survival
advantage for patients in the trial districts only obtained for
the period beyond 2 years following diagnosis.
Table X Studies of miscellaneous sites
Years of No. of
Reference diagnosis Setting patients Site Variables studied Outcome measures
Edge et al. (1993) 1989-90 Selected university 223 Pancreas Number of patients Operative mortality
hospitals, USA at hospital
Lustig et al. 1973-74 Seklted 1,220 Larynx Type of hospital Actuanal survival and
(1984, 1991) and 1978 hospitals, USA recurrence free
survival
Gill et al. (1988) 1968-82 South Thames 194 Bone Type of hospital Actuarial survival
regions, England (osteosarcoma)
Brewer et al. (1971) 1962-70 Illinois, USA 138 Choriocarcinoma Type of hospital Mortality;
106 Invasive remission rate
hydatid mole
Gulliford et al. (1991) 1982 South Thames 574 Bladder Grade and specialty Actuarial survival
regions, England of surgeon
Karjalainen & 1979-85 Finland 1,978 Multiple District policy on Actuarial relative
Palva (1989) myeloma entry to clinical survival
trials358 C.A. STILLER
Childhood cancers (Table XI)
During the mid-1960s, at the very beginning of the era of
effective chemotherapy for childhood acute lymphoblastic
leukaemia, the median survival time of children treated by
clinicians associated with the Medical Research Council
Working Party which organised national trials in Great Brit-
ain for this disease was twice that of children treated
elsewhere (MRC, 1971), but no significant difference in sur-
vival was found between children treated in accordance with
MRC trial protocols and those treated according to other
regimens; age was allowed for in the analysis. For children
with ALL diagnosed in Britain during 1971-84 there was a
significant trend towards higher survival rates among chil-
dren who were treated at hospitals seeing larger numbers of
children with the disease (Stiller & Draper, 1989). Children
entered in the MRC trials had a significantly higher survival
rate than those who were not. Trial entry had little effect on
survival at centres treating larger numbers of children, and
the effect of centre size for trial patients was also small; by
far the lowest survival rates were for children who were
treated at centres with few patients and were not included in
the trials. These results were essentially unchanged when
allowance was made for age and white cell count, which were
both important prognostic factors. When the analysis was
limited to children surviving at least 3 months from diag-
nosis, thereby presumably eliminating all those who failed to
achieve remission, the effects of trial entry and size of centre
remained highly significant. A broadly similar pattern was
found in the Greater Delaware Valley, United States, with a
significantly higher survival rate at specialist paediatric
cancer centres and for children treated on protocols, but
relatively little variation with type of centre within the pro-
tocol group (Meadows et al., 1983).
For acute non-lymphocytic leukaemia diagnosed in Britain
during 1975-88, entry to a trial and treatment at a teaching
hospital were both associated with a higher survival rate in
an analysis allowing for age at diagnosis; these effects were
largely confined to the first few months following diagnosis,
but untreated children were excluded (Stiller & Eatock,
1994).
In two studies of children in Britain with retinoblastoma
diagnosed during successive calendar periods (Lennox et al.,
1975; Sanders et al., 1988), survival rates were analysed
allowing for laterality and stage. In both periods, survival
rates were highest at the national referral centre treating
about 40% of all patients, lower at other eye hospitals and
lowest of all at other non-specialist hospitals. Among child-
ren with Wilms' tumour diagnosed during 1970-73, survival
rates allowing for age and stage were significantly higher for
children who were included in the MRC trial than for those
who were eligible but not included; patients who had surgery
at specialist teaching or children's hospitals had a higher
survival rate, but there was no relationship between survival
and the number of children treated at a radiotherapy centre
(Lennox et al., 1979). For children with medulloblastoma
diagnosed during 1971-77, survival rates did not vary with
the number of patients in the series at the neurological or
radiotherapy centre (Stiller & Lennox, 1983). Survival rates
for children with Hodgkin's disease, non-Hodgkin's lym-
phoma, neuroblastoma, Wilms' tumour, osteosarcoma,
Ewing's sarcoma and rhabdomyosarcoma diagnosed during
1977-84 were compared between paediatric oncology centres
and other hospitals in Britain (Stiller, 1988); age at diagnosis
was allowed for in these analyses. Survival rates were
significantly higher at paediatric oncology centres for non-
Hodgcin's lymphoma, Ewing's sarcoma and rhabdomyosar-
coma, and for osteosarcoma diagnosed during 1981-84. No
difference was found in survival with type of hospital for
Hodgkin's disease or Wilms' tumour, both ofwhich had high
survival rates. For neuroblastoma there was no significant
difference in survival between treatment centre types, but
paediatric centres appeared to treat a much higher propor-
tion of patients with late-stage disease. During 1977-91,
children with extracranial malignant germ-cell tumours had a
higher survival rate if they were initially treated at a paediat-
ric oncology centre (Mann & Stiller, 1993); this analysis
allowed for period of diagnosis, since survival rates and the
Table XI Studies of childhood cancer
Years of No. of Diagnostic
Reference diagnosis Setting patients group Variables studied Outcome neasures
MRC (1971) 1963-67 England and Wales 879 ALL Specialist centres; Median survival
trial protocol
Meadows et al. (1983) 1970-75 Greater Delaware 327 ALL Specialist centres Actuarial survival
Valley, USA national protocol
Stiller & Draper (1989) 1971-84 Great Britain 4,697 ALL Patients per hospital; Actuarial survival
entry to trials
Stiller & Eatock (1994) 1975-88 Great Britain 818 ANLL Type of hospital; Actuarial survival
entry to trials
Lennox et al. (1975) 1962-68 Great Britain 268 Retinoblastoma Specialist centres Four year survival
Sanders et al. (1988) 1969-80 Great Britain 431 Retinoblastoma Specialist centres Three year survival
Lennox et al. (1979) 1970-73 Great Britain 313 Wilms' tumour Specialist centres; Three year survival
entry to trial
Griffel (1977) 1950-72 New York, USA 127 Wilms' tumour Specialist centres Five year survival
Duffner et at. (1982) 1968-79 Connecticut, USA 278 Brain tumours Specialist centres Actuarial survival
Stiller & Lennox (1983) 1971 -77 Great Britain 368 Medulloblastoma Patients per hospital Actuarial survival
Kramer et al. (1984) 1970-79 Greater Delaware 147 Wilms' tumour Specialist centres Actuarial survival
Valley. USA 76 Medulloblastoma
87 Rhabdomyosarcoma
Stiller (1988) 1977-84 Great Britain 435 Hodgkin's disease Specialist centres Actuarial survival
497 NHL
486 Neuroblastoma
483 Wilms' tumour
240 Osteosarcoma
234 Ewing's sarcoma
351 Rhabdomyosarcoma
Mann & Stiller (1994) 1977-91 Great Britain 555 Germ cell Specialist centres Actuarial survivalCENTRALISED TREATMENT, TRIAL ENTRY AND SURVIVAL 359
proportion of children referred to paediatric oncology centres
both varied during the study period. The difference was
highly significant for boys with testicular tumours, for whom
the 5 year survival rate at paediatric oncology centres during
1987-91 was 100%.
In New York State during 1960-72 children with Wilms'
tumour who lived in and around Buffalo were more lily to
be treated at hospitals with larger numbers of Wilms' tumour
patients and also had a substantially higher survival rate
(Griffel, 1977). In Connecticut during 1968-77, the survival
rate was higher at university cancer centres for children with
medulloblastoma or brain stem glioma but not for ependy-
moma or astrocytoma (Duffler et al., 1982). In the Greater
Delaware Valley during 1970-79, children with medulloblas-
toma or rhabdomyosarcoma had a significantly higher 3 year
disease-free survival rate if they were treated at a specialist
cancer centre, but survival did not vary between types of
hospital for children with Wilms' tumour (Kramer et al.,
1984).
Although there is at first sight an impressively large number
of studies of survival of cancer patients in relation to patterns
of organisation of medical care, the results of different
studies can hardly ever be formally pooled to produce a new,
more precise estimate of the effect of the factors being in-
vestigated. Very few studies have been made of these ques-
tions in relation to any one type of cancer - in the present
review, the largest number found for any site was seven. Two
studies of the same site seldom ask the same questions.
Studies have taken place over a period of decades and in a
wide range of settings. While the effectiveness of particular
treatments may be relatively constant with respect to time or
geographical location, it is less safe to assume that the same
will be true for the effects of patterns of organisation of
care.
Sources ofbias
Studies of survival rates can be compromised by several types
of bias. If patients with a better prognosis are selectively
referred to major centres, as was found in a study of colorec-
tal cancer at Columbia University Comprehensive Cancer
Center (Neugut et al., 1991), this could produce an artificial
appearance of a better chance of survival at those centres.
Similarly, patients included in trials may have a higher sur-
vival rate than those who are not because many of the
excluded patients are ineligible, often because of poor prog-
nostic features, as was found for example in the study of
stomach cancer by Ward et al. (1992). For these reasons,
more weight should be attached to studies in which some
attempt was made to adjust for prognostic factors which
might be confounders in any analysis of survival in relation
to patterns of care. Even then, results need to be interpreted
with caution. If patients at large centres undergo more
thorough investigation, some may be assigned to a higher
stage than if they had been treated at another hospital, as
was found in the study of lung cancer by Greenberg et al.
(1991). Therefore, measures of disease severity which are
likely to be the same for an individual patient regardless of
where that patient is treated are preferable; these include
white cell count for leukaemia and performance status (Kar-
nofsky & Burchenal, 1949) for a wide range of cancers.
Limiting the analysis to patients who survive for at least a
specified short period after diagnosis, or long enough to
receive a particular type of treatment, can also reduce bias by
excluding many subjects who probably had little chance of
remission. This approach, however, is obviously inapprop-
riate for studying short-term mortality following surgery.
Some of the problems of referral bias which arise when
patients are compared on the basis of hospital of treatment
can be avoided by using instead a classification based on area
of residence, as in the series of studies from Finland. Inter-
pretation is still problematic, however, as areas coniing
specialist treatment centres may be of a different socio-
economic status. Delay in diagnosis, attributable at least in
part to delayed presentation, may vary between areas
(Launoy et al., 1992), and the presene of screening program-
mes can also affect the distribution of disease severity
between areas (Pickering et al., 1992).
There is also the possibility of publication bias, whereby
studies whose conclusions point in a partiular direction are
more likely to appear in journals, but for this review this has
been dealt with to some extent by obtaining statements from
cancer regitries whose data had been used in published
studies that they had not also contributed to other studies
which had remained unpublished.
Effects ofhospital andprotocol
Despite the limitations discussed above, there are some
discernible patterns in the material reviewed here. A substan-
tial proportion of studies reported higher survival rates for
patients who were treated at major centres dealing with
largr numbers of cases or at teaching hospitals and other
specialist centres or for patients who were treated according
to sandard protocols, usually within trials. The most
obvious explanation for these results is that greater cinical
experience and standardisation of treatment are likely to
produce higher survival rates. There was no consistent pat-
tern among the studies reviewed of this effect being limited to
rare or common cancers, or to cancers with an especially
good or poor prognosis.
Although patients treated at specialist centres or in trials
frequently have higher survival rates, and there is no evidence
that such treatment results in a lower survival rate, there
might nevertheless be concern that improvements in survival
which are often associated with more intensive therapy are
counterbalanced by an increase in treatment-related mor-
bidity. Causes of death have hardly ever been studied in
relation to patterns of care. Among children with non-
Hodgkin's lymphoma treated in Britain during 1977-85,
treatment-related mortality, at least in the medium term, was
no higher at paediatric oncology centres than elsewhere
(Robertson et al., 1992).
For some tumours, particularly those with a good prog-
nosis, non-protocol treatment can be more intensive. Among
residents of the West Midlands region of England treated for
parotid pleomorphic adenoma during 1977-86, the propor-
tion of patients receiving radiotherapy, which is not now
recommended for this disease, ranged from zero to 57%
among the nine centres treating at least one patient a year
during the study period (Parry et al., 1993). During 1980-82,
children with Wihns' tumour in Britain who were neither
included in the national trial nor treated by a paediatric
oncologist tended to be overtreated by comparison with cur-
rent recommendations, mostly by receiving more radio-
therapy than would have been given had they been included
in the trial (Pritchard et al., 1989). In both ofthese examples,
the apparently unnecessary radiotherapy could give rise to
second malignancies and other late effects.
Few studies have investigated the effect of size or type of
treatment centre on the survival of patients in clinical trials
or treated on protocols. In the United States, no difference
was found in survival rates between major centres and local
community hospitals for any of the nine cancer sites included
in tnals sponsored by the Eastern Cooperative Oncology
Group during 1976-81 (Begg et al., 1982), or for five studies
of the Radiation Therapy Oncology Group (Gillespie et al.,
1986). In both thpe Britsh and American studies of childhood
ALL there was no indication that survival rates for chikin
entered in trials or treated according to standard protocols
varied with size or type of treatment centre (Meadows et al.,
1983; Stiller & Draper, 1989); an unusually high survival rate
was achieved at one centre in Britain during the 1970s which
had only a moderate number ofpatients, but where there was
believed to be an unusually strong emphasis for that period
on strict adherence to the treatment protocol (Eden et al.,360 C.A. STILLER
1988). Two studies of testicular cancer found that, among
men receiving protocol treatment, survival rates were higher
at a single centre treating very large numbers of patients
(Aass et al., 1991; Harding et al., 1993), but this could
equally be due to size of centre or to some other at-
tribute.
Studies ofindividual clinicians
In addition to the studies of survival in relation to size or
type of treatment centre reviewed here, there have been a
number of studies in which patients have been categorised
according to measures of experience of the treating surgeon.
Studies of oesophageal and gastric cancer in the West Mid-
lands region of England have indicated that short-term sur-
vival is better for the patients of surgeons who do larger
numbers of operations (Matthews et al., 1986; Allum et al.,
1989). Two studies of colorectal cancer have shown wide
variability in mortality between surgeons (Phillips et al.,
1984; McArdle & Hole, 1991), but this appeared to be un-
related to the number of operations performed. Studies of
survival in relation to seniority of surgeon may be especially
problematic since if they were to show a higher survival rate
for patients operated on by consultants then this might sug-
gest that such operations should wherever possible be carried
out by consultants, but such a policy would be irreconcilable
with the fact that the junior surgeons undergoing training
today are the consultants of tomorrow. In studies of colorec-
tal and bladder cancer, however, mortality was similar
among patients operated on by consultants and trainee
surgeons after allowance was made for disease severity (Phil-
lips et al.. 1984; Gulliford et al., 1991).
Rare and common cancers
In the absence of formal comparative studies it has been
suspected for some time, on the basis of uncontrolled com-
parison of national survival rates or of those from non-
specialist units, that treatment of rare cancers such as
testicular tumours in specialist units results in higher survival
rates (Bagshawe et al., 1985; Thornhill et al., 1988b). It is
now widely accepted that rare cancers, particularly those for
which there have been substantial improvements in the
effectiveness of treatment, should be treated in specialist
centres. It is sometimes felt, however, that treatment of com-
mon cancers need not be organised in the same way (King-
ston et al., 1992). In the present review there are several
examples of common cancers for which treatment in a speci-
alist centre, usually a teaching hospital, apparently conferred
no benefit. This is perhaps not surprising if the higher sur-
vival rate for rare cancers at specialist centres is really due to
greater clincal experience, since many district hospitals will
also have treated large numbers of patients with cancers of
sites such as the bowel, lung and breast. Studies relating
survival to the number of patients seen at a hospital rather
than to the type of hospital may well sometimes be more
relevant. For ovarian carcinoma, however, a relatively com-
mon cancer but one for which there have been important
developments in therapy, the studies reviewed above indicate
that specialist treatment is associated with higher survival.
Socioeconomic and demographicfactors
Changes in the provision of health care, particularly with the
containment of costs as a primary objective, can give rise to
anxiety over the effects on equity, i.e. the principle that
outcome should as far as possible be unaffected by such
factors as area of residence, social class, ethnic group or age
(Pollock, 1993). Survival rates may vary between areas as a
result of delayed presentation which could be due to defici-
encies in the effectiveness of screening, primary care or health
education. They could also, however, vary because of differ-
ences in treatment if patients are more likely to be referred to
a major centre if they live closer to that centre or are of
higher socioeconomic status. Many studies have found varia-
tions in survival with social class; the relative contributions
of patient-related and treatment-related factors are often
unknown, but it seems likely that delayed presentation
among people of low socioeconomic status accounts for
much of the difference (Kogevinas et al., 1991). In the United
States, blacks have a poorer survival rate than whites for
many cancer sites (Howard et al., 1992). Part of the differ-
ence is accounted for by lower socioeconomic status and later
presentation, but again the contribution of variations in pat-
terns of care to differences in survival between ethnic groups
is unknown.
The treatment of cancer in the elderly has provoked con-
troversy (Fentiman, 1991). Nearly all of the studies reviewed
here had an upper age limit, and there is no evidence as to
the effect of patterns of organisation of care on survival rates
specifically for the elderly. Most trials have themselves ex-
cluded older people, often because it was felt that they would
not withstand intensive treatment, with the result that there
is little objective evidence as to- what is the best treatment for
them. Among women enrolled in trials of breast cancer in the
south-eastern United States, response rates, survival and toxi-
city were all similar for patients aged under or over 70
(Christman et al., 1992). Lack of access to transport can
often be a reason for undertreatment of elderly patients
(Goodwin et al., 1993).
Other outcome measures
This review has concentrated on studies of survival rates that
have death or, less frequently, recurrence as the end point.
Survival is often both the most important and the most easily
measurable outcome. For many cancers, however, particular-
ly those of advanced stage and extremely poor prognosis,
treatment is essentially palliative and substantial variations in
survival rates are unlikely to occur. There are apparently no
published studies of palliation and quality of life in relation
to patterns of organisation ofcare for these patients, and this
is clearly an important area for future research.
For cancers with a relatively good prognosis, quality of life
as well as absolute survival is also important, though again
there appears to be little published research in relation to
organisational factors. A population-based study in Washing-
ton State, USA, found that women with early-stage breast
cancer were less likely to receive breast-conserving surgery
and radiotherapy rather than mastectomy if they lived out-
side the region's major urban centre and particularly if they
lived in a county without its own radiotherapy facilities
(Lazovich et al., 1991). In a study of women with early-stage
breast cancer treated at 19 British hospitals, however, there
were no significant differences in the incidence of anxiety and
depression between women who had breast-conserving
surgery or mastectomy (Fallowfield et al., 1990). The rates of
psychiatric morbidity in both treatment groups were similar
to those observed in a previous randomised trial of the two
forms of treatment.
Conch9dow
In conclusion, referral to a specialist centre or to a hospital
treating many patients with the disease, or inclusion in a
clinical trial, is often linked with a higher survival rate for the
cancers which have been studied; there is no evidence that
centralised referral or treatment according to protocols leads
to lower survival rates. Some published studies antedate the
introduction of current methods of treatment, and research
has also been carried out in populations covered by a wide
range of health care systems. In order to establish the cancer
types for which standardised referral and treatment are most
beneficial, and to monitor the effects on survival of new
arrangements for the organisation of medical care, further
research is needed. Population-based cancer registries, cover-
ing an increasing proportion of the world's population, areCENTRALISED TREATMENT, TRIAL ENTRY AND SURVIVAL 361
an invaluable source of data for such studies. In Britain,
further studies will be facilitated if the cancer registration
system adopts the recommendation of the most recent
national review committee that lists of patients enrolled in
trials are linked with regional and national registries (Work-
ing Group of the Registrar General's Advisory Committee,
1990).
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is supported by the Department of Health and the Scottish Home
and Health Department.
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